Valinomycin

Cyclic Depsipeptide IonophoreRx: ResearchCompound: Research

Also known as: Antibiotic K, Antibiotic X-464, Cyclododecadepsipeptide ionophore, Valinomycin A, VLM

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source Valinomycin at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Valinomycin is a cyclic dodecadepsipeptide produced by Streptomyces species. It acts as a high‑affinity potassium ionophore and exhibits antimicrobial activity. Primarily used as a research tool to study ion transport and membrane physiology; not approved for therapeutic use.

Mechanism of Action

Facilitates selective K⁺ ion transport across lipid membranes, disrupting ion gradients and membrane potential

Routes of Administration

In VitroIntraperitonealIntravenousTopical

Goals & Uses

  • Antimicrobial activityAnti InfectiveLow
  • Anticancer activityOncologyLow
  • Antiviral activity (SARS-CoV)AntiviralLow
  • Ion channel / transport researchBasic ResearchHigh
  • Research tool – membrane potential studiesBasic ResearchHigh
  • Potassium ionophore researchResearch ToolHigh
  • Antimicrobial screeningResearch ToolModerate

Contraindications

  • Human therapeutic administrationClinical UseHigh
  • Renal impairmentOrgan DysfunctionHigh
  • Cardiac arrhythmia riskCardiovascularHigh

Adverse Effects

  • Mitochondrial uncouplingMetabolicCommon
  • Hyperkalemia / hypokalemiaElectrolyte DisturbanceUnknown
  • Apoptosis inductionCellular ToxicityCommon
  • HemolysisHematologicUncommon
  • CytotoxicityCell ViabilityCommon

Drug Interactions

  • Cardiac glycosides (e.g., digoxin)High
  • Mitochondrial complex inhibitors (e.g., rotenone)High
  • Potassium-sparing diureticsHigh

Population Constraints

  • All human populations (therapeutic use)GeneralAbsolute
  • Pediatric patientsAgeAbsolute
  • Patients with cardiac diseaseCardiovascularAbsolute
  • Pregnant individualsReproductiveAbsolute

Regulatory Status

  • European UnionUnapprovedNo marketing authorization; sold as a laboratory reagent
  • United StatesUnapprovedNot FDA‑approved; available only for research
  • United KingdomUnapprovedNot licensed for medicinal use

Not approved by FDA, EMA, or any major regulatory authority for human therapeutic use. Used exclusively as a laboratory research reagent. Some interest in repurposing as an antiviral or anticancer agent remains at the preclinical stage.

Evidence & Sources

No sources recorded yet.

Frequently Asked Questions

What is Valinomycin?

Valinomycin is a cyclic dodecadepsipeptide produced by Streptomyces species. It acts as a high‑affinity potassium ionophore and exhibits antimicrobial activity. Primarily used as a research tool to study ion transport and membrane physiology; not approved for therapeutic use.

What is Valinomycin used for?

Valinomycin is educationally associated with: Antimicrobial activity, Anticancer activity, Antiviral activity (SARS-CoV), Ion channel / transport research, Research tool – membrane potential studies, Potassium ionophore research, Antimicrobial screening. Educational only — not medical advice.

How is Valinomycin administered?

Recorded routes of administration: In Vitro, Intraperitoneal, Intravenous, Topical.

What are the potential side effects of Valinomycin?

Reported adverse effects include: Mitochondrial uncoupling, Hyperkalemia / hypokalemia, Apoptosis induction, Hemolysis, Cytotoxicity. This list is not exhaustive — consult a qualified clinician.

Who should avoid Valinomycin?

Recorded contraindications: Human therapeutic administration, Renal impairment, Cardiac arrhythmia risk. Consult a qualified clinician before use.